Loncastuximab Tesirine in a Frail, Heavily Pretreated Patient With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Case Report

Read full text Summarise with VIRAT
Authors: Reyad Dada, Refaei Belal Ibrahim
Cited by: 0
References: 14

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Loncastuximab tesirine may offer a feasible, well‐tolerated option for frail, heavily pretreated patients with relapsed/refractory DLBCL and poor performance status when intensive therapies are unsuitable, achieving durable remission with manageable fluid retention through careful monitoring, spironolactone‐based treatment, and dose modification.

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment CAR-T cell therapy research Chronic Lymphocytic Leukemia Research

Publication details

Journal / source
Clinical Case Reports
Volume
14
Issue
4
Pages
e72234
Publication date
30 March 2026
Language
EN